Table 5.
Parameters of primary and recurrent Plasmodium vivax blood infections from ISD patients
Patient | Age/sex | Primary blood infection | Recurrent infection by microscopy | Serology (ELISA OD value/405NM; cut off value 0.25) | ||||
---|---|---|---|---|---|---|---|---|
(p/µl) asexual parasitaemia | RFLP: cspr-msp3α/β | Daya | Clinical symptoms | (p/µl) asexual parasitaemia | Genotype cspr-msp3α/β | |||
P6 | 3/F | 2364 | vk247-A | D241b | Yes | 875 | vk247-A | 0.16D211 → 2.57 D241 |
P7 | 17/F | 10,766 | vk210-B/III | D236b | Yes | 14,218 | vk210-B/III | 0.04D218 → 1.49 D236 |
P15 | 62/F | 675 | vk210-B/IV | D312b | Yes | 246 | vk210-B/IV | 0.29D301 → > 3.0D312 |
P17 | 36/F | 480 | vk210/247-B/III | D108b | Yes | 8485 | vk247-A/I | 0.18D89 → 2.1D209 |
P35 | 20/F | 2241 | vK210-C/V | D336b | Yes | 846 | vK210-C/V | 0.18D308 → 1.88D336 |
P37 | 9/M | 17,598 | vK210-C/V | D287b | Yes | 866 | vK210-C/V | 0.16D287 → 1.67D308 |
P44 | 60/M | 2951 | vk210-C/VI | D282b | Yes | 844 | vk210-C/VI | 0.18D244 → 0.53D282 |
P56 | 42/F | 7960 | vk210-C/V | D178b | Yes | 1570 | vk210/247-A/I | 0.41D147 → 1.12D178 |
P62 | 26/M | 4319 | vk210/247-C/II | D216b | Yes | 2594 | vk210-C/II | 0.15D183 → 2.48 D216 |
P72 | 12/M | 8059 | vk210-B/III | D98c | Yes | 3505 | vk210-B/III | 0.963D92 → 2.03D98 |
Truncated (complete information is given in Additional file 6)
M male, F female, RFLP restriction fragment length polymorphism, cspr circumsporozoite gene central repeat type, msp3α merozoite surface protein 3α/β genes
aDay of sample collection
bAfter diagnosed with P. vivax, T14 was administered
cContinued the ISD treatment; P44, was the only patient that had a second recurrent episode after T14 was administered; D348 was positive by microscopy